Virginia is currently home to 1852 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Richmond, Charlottesville, Norfolk and Fairfax. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
NCT05785741
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1310 in subjects with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/03/2025
Locations: NEXT Virginia, Fairfax, Virginia
Conditions: Advanced Solid Tumor
Register for Updates
A Study of PHN-010 in Patients with Advanced Solid Tumors
NCT06457997
Recruiting
This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of PHN-010, a novel antibody-drug conjugate (ADC), in patients with advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: NEXT - Virginia, Fairfax, Virginia
Conditions: Lung Cancer, Colon Cancer, Endometrial Cancer, Ovarian Cancer, Cervical Cancer, Advanced Solid Tumor, Advanced Cancer
Register for Updates
The Effect of Work Requirements in SNAP in Virginia
NCT04888832
Recruiting
More than a dozen states have proposed or plan to implement work requirements in Medicaid, and similar requirements already exist nationally in the Supplemental Nutritional Assistance Program (SNAP), yet evidence on the effects of these policies is limited. In cooperation with the state of Virginia, the investigators plan to conduct a randomized controlled trial studying the impacts of work requirements in public programs on insurance coverage, SNAP participation, employment, and health, with a... Read More
Gender:
ALL
Ages:
Between 18 years and 49 years
Trial Updated:
02/28/2025
Locations: Virginia Department of Social Services (Home Office), Glen Allen, Virginia
Conditions: Health Disparities, Food Security
Register for Updates
Remote Monitoring and Management of Chemotherapy Induced Peripheral Neuropathy
NCT04763356
Recruiting
This is a prospective randomized trial designed to investigate a new care model for patients who suffer from nerve damage from chemotherapy called chemotherapy induced peripheral neuropathy (CIPN). All participants in the study will report their CIPN symptoms daily using a website, app or phone for 12 weeks. In one group the data will be collected and participants will be encouraged to reach out to their treating doctors for uncontrolled symptoms. These participants' doctors can prescribe any tr... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: Virginia Commonwealth University Massey Cancer Center, Richmond, Virginia
Conditions: Chemotherapy-induced Peripheral Neuropathy
Register for Updates
Multi-level Determinants of Implementation and Sustainment in the Education Sector
NCT04430010
Recruiting
The purpose of this study is to learn more about teachers' sustainment of use of core components of BEST in CLASS in a follow-up study.
Gender:
ALL
Ages:
5 years and above
Trial Updated:
02/28/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Evidence Based Programs in Schools
Register for Updates
Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors
NCT02715284
Recruiting
This is a multi-center, open-label, first-in-human Phase 1 study evaluating the anti-programmed death receptor 1 (anti-PD-1) antibody dostarlimab (also known as TSR-042) n participants with advanced solid tumors who have limited available treatment options. The study will be conducted in 2 parts with Part 1 consisting of safety evaluation, pharmacokinetics (PK), and pharmacodynamics (PDy) of escalating doses of dostarlimab. Dose escalation will be based on ascending weight-based dose levels (DLs... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/28/2025
Locations: GSK Investigational Site, Charlottesville, Virginia
Conditions: Neoplasms
Register for Updates
Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT06425926
Recruiting
GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary effect through selective inhibition of regulatory T-cells (Tregs).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Virginia Commonwealth University, Richmond, Virginia
Conditions: Melanoma Stage IV, Solid Tumor
Register for Updates
Repositioning Immunotherapy in VetArans With Lung Cancer
NCT06275360
Recruiting
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Hunter Holmes McGuire VA Medical Center, Richmond, VA, Richmond, Virginia
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study of CUSP06 in Patients with Platinum-Refractory/Resistant Ovarian Cancer and Other Advanced Solid Tumors
NCT06234423
Recruiting
This phase 1 study will evaluate the safety, tolerability, pharmacokinetics, and efficacy of CUSP06 in patients with platinum-refractory/resistant ovarian cancer and other advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: NEXT Oncology, Fairfax, Virginia
Conditions: Ovarian Cancer, Solid Tumor
Register for Updates
A Study of DB-1303/BNT323 vs Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Metastatic Breast Cancer (DYNASTY-Breast02)
NCT06018337
Recruiting
The goal of this clinical trial is to assess the efficacy of DB-1303/BNT323 compared with investigator's choice chemotherapy in terms of progression-free survival (PFS) by blinded independent central review (BICR) in the HR+, HER2-low (immunohistochemistry \[IHC\]2+/in situ hybridization \[ISH\]- and IHC 1+) population.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Research Site 1108-0, Fairfax, Virginia
Conditions: Metastatic Breast Cancer
Register for Updates
A Phase 1, First in Human Study of TORL-4-500 in Patients with Advanced Cancer
NCT06005740
Recruiting
This first-in-human study will evaluate the safety, tolerability, pharmacokinetics, and antitumor activity of TORL-4-500 in patients with advanced cancer. For Part 1, any advanced or metastatic solid tumor malignancy will be evaluated including, for example, adrenocortical carcinoma (ACC).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: Virginia Cancer Specialists, Lexington, Virginia
Conditions: Advanced Solid Tumor, Hepatocellular Carcinoma
Register for Updates
Testing Ipilimumab and Nivolumab Combination With or Without Cabozantinib in People >= 18 Years Old With Advanced Soft Tissue Sarcoma
NCT05836571
Recruiting
This phase II trial compares the effect of immunotherapy with ipilimumab and nivolumab alone to their combination with cabozantinib in treating patients with soft tissue sarcoma that has spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozan... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/27/2025
Locations: University of Virginia Cancer Center, Charlottesville, Virginia
Conditions: Locally Advanced Extraskeletal Myxoid Chondrosarcoma, Locally Advanced Leiomyosarcoma, Locally Advanced Liposarcoma, Locally Advanced Undifferentiated Pleomorphic Sarcoma, Locally Advanced Unresectable Soft Tissue Sarcoma, Metastatic Undifferentiated Pleomorphic Sarcoma, Metastatic Soft Tissue Sarcoma, Unresectable Leiomyosarcoma, Unresectable Liposarcoma, Unresectable Undifferentiated Pleomorphic Sarcoma
Register for Updates